Literature DB >> 18619557

MicroRNAs in diseases and drug response.

Michela Garofalo1, Gerolama Condorelli, Carlo Maria Croce.   

Abstract

MicroRNAs (miRNAs) are short non-coding RNAs involved in post-transcriptional regulation of gene expression. Since the discovery of the first miRNA gene lin-4 in C. elegans, over 500 miRNAs have been identified in humans and the list is growing. Their biological importance, initially demonstrated in cancer, was also more recently discovered in many other pathologies like Alzheimer's disease, Parkinson's disease, viral infections, diabetes, and myopathies. In the present review we will summarize miRNA profiling studies in human diseases and discuss the newly discovered link between microRNAs and drug response. An understanding of how microRNAs influence the body's response to certain drugs and how these affect the expression of microRNAs, will be of key importance in developing drugs with greater safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619557     DOI: 10.1016/j.coph.2008.06.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  37 in total

Review 1.  microRNAs in heart disease: putative novel therapeutic targets?

Authors:  Gianluigi Condorelli; Michael V G Latronico; Gerald W Dorn
Journal:  Eur Heart J       Date:  2010-01-29       Impact factor: 29.983

2.  A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.

Authors:  Liqin Du; Robert Borkowski; Zhenze Zhao; Xiuye Ma; Xiaojie Yu; Xian-Jin Xie; Alexander Pertsemlidis
Journal:  RNA Biol       Date:  2013-09-30       Impact factor: 4.652

Review 3.  The potential role of miR-124-3p in tumorigenesis and other related diseases.

Authors:  Qian Li; Shuqing Liu; Jinsong Yan; Ming-Zhong Sun; Frederick T Greenaway
Journal:  Mol Biol Rep       Date:  2021-04-20       Impact factor: 2.316

4.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

5.  Identification of senescence-inducing microRNAs in normal human keratinocytes.

Authors:  Ki-Hyuk Shin; Ana Pucar; Reuben H Kim; Susan D Bae; Wei Chen; Mo K Kang; No-Hee Park
Journal:  Int J Oncol       Date:  2011-07-01       Impact factor: 5.650

Review 6.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

7.  Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy.

Authors:  Melissa M Lee; Jessica L Childs-Disney; Alexei Pushechnikov; Jonathan M French; Krzysztof Sobczak; Charles A Thornton; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

8.  The role of flexibility in the rational design of modularly assembled ligands targeting the RNAs that cause the myotonic dystrophies.

Authors:  Matthew D Disney; Melissa M Lee; Alexei Pushechnikov; Jessica L Childs-Disney
Journal:  Chembiochem       Date:  2010-02-15       Impact factor: 3.164

9.  Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints.

Authors:  Alessandro Laganà; Stefano Forte; Francesco Russo; Rosalba Giugno; Alfredo Pulvirenti; Alfredo Ferro
Journal:  J RNAi Gene Silencing       Date:  2010-05-24

10.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.